Press releases

Press releases

16 December 2014  - Paris (France)

Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors

16 December 2014  - Paris (France)

François Garnier appointed Executive Vice President, General Counsel of Ipsen

12 December 2014  - Paris (France)

Ipsen announces that the International Breast Cancer Study Group (IBCSG) presented phase 3 results evaluating the use of ovarian suppression to adjuvant treatment with tamoxifen

28 November 2014  - Paris (France)

Ipsen announces FDA acceptance of filing for Dysport® in the treatment of upper limb spasticity in adult patients

20 November 2014  - Paris (France)

Ipsen and CNRS create the "Archi-Pex" joint research and innovation lab, in collaboration with the University of Rennes 1 and CEA

18 November 2014  - Paris (France)

Ipsen and the Salk Institute renew their agreement for discovery research in medical sciences

06 November 2014  - Paris (France)

Otonomy obtains rights to gacyclidine data from Ipsen to support development of OTO-311 as a treatment for tinnitus

29 October 2014  - Paris (France)

Ipsen: sales in the 3rd quarter and first nine months of 2014

22 October 2014  - Paris (France)

Lexicon and Ipsen enter into ex-North America/Japan licensing and commercialization agreement for telotristat etiprate

10 October 2014  - Paris (France)

Ipsen announces positive results from phase III clinical study of Decapeptyl® (triptorelin pamoate) 11.25 mg administered by subcutaneous route to prostate cancer patients